LCS
IMDX

Levin Capital Strategies’s Insight Molecular Diagnostics IMDX Stock Holding History

Levin Capital Strategies’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-525
Closed -$2.42K – 301
2023
Q2 		$2.42K Hold
525
– – ﹤0.01% 271
2023
Q1 		$3.72K Hold
525
– – ﹤0.01% 241
2022
Q4 		$3.37K Hold
525
– – ﹤0.01% 242
2022
Q3 		$8K Buy
+525
New +$9.09K ﹤0.01% 231

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Levin Capital Strategies's IMDX Position: Q3 2023 in Review

Levin Capital Strategies sold out of Insight Molecular Diagnostics (IMDX) in Q3 2023, closing a stake of 525 shares — an estimated $2.42K sold.

Levin Capital Strategies first reported a position in IMDX in Q3 2022 and held it in 4 quarters. The position peaked at $8K in Q3 2022. 30 funds tracked by Wall St. Rank hold IMDX as of Q3 2023.

  • Levin Capital Strategies reported no remaining Insight Molecular Diagnostics position as of Q3 2023 after selling out during the quarter.
  • Levin Capital Strategies sold 525 Insight Molecular Diagnostics shares in Q3 2023, an estimated $2.42K.
  • Levin Capital Strategies first reported a position in Insight Molecular Diagnostics in Q3 2022 and held it in 4 quarters.
  • Levin Capital Strategies's Insight Molecular Diagnostics position peaked at $8K in Q3 2022.
  • 30 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2023.

Based on Levin Capital Strategies's 13F filing for Q3 2023, filed 31 Oct 2023.